abs352.txt	purpose		immune	checkpoint	inhibitors	designed	to	revert	tumor-inducedimmunosuppression	have	emerged	as	potent	anticancer	therapies	tryptophanmetabolism	represents	an	and	targeting	this	pathway'srate-limiting	enzyme	ido1	is	actively	being	investigated	clinically	here	westudied	the	intermediary	metabolism	of	tryptophan	in	glioblastoma	andevaluated	activity	inhibitor	gdc-0919	both	alone	incombination	with	radiation	(rt)	experimental	design	lc/gc-ms	expressionprofiling	was	performed	for	metabolomic	genomic	analyses	patient-derivedglioma	immunocompetent	mice	were	injected	orthotopically	geneticallyengineered	murine	glioma	cells	treated	or	combined	withrt	flow	cytometry	on	isolated	tumors	determine	immuneconsequences	individual	treatments	results	integrated	cross-platform	analysescoupling	global	gene	expression	profiling	identified	aberranttryptophan	a	metabolic	node	specific	mesenchymal	andclassical	subtypes	demonstrated	inhibition	ofthis	effectively	crossed	blood-brain	barrier	although	asingle	agent	did	not	demonstrate	antitumor	it	had	strong	potentialfor	enhancing	rt	response	which	further	augmented	ahypofractionated	regimen	involves	immunestimulation	reflected	by	increases	activated	cytotoxic	t	wasbalanced	reactivation	increase	ido1expression	regulatory	(treg)	mitigated	rt-induced	tregs	andenhanced	t-cell	activation	conclusions	ametabolic	combining	enhancestherapeutic	mitigating	immunosuppression	clin	cancer	res	24(15)	3632-43	Â©2018	aacr
